Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zymeworks has received $8.1m in funding to enhance its Azymetric and AlbuCORE platforms and to develop protein therapeutics pipeline in the areas of cancer, autoimmunity and inflammatory diseases.
Subscribe to our email newsletter
The funding was granted by CTI Life Sciences Fund (CTI), Advanced Biotechnologies Venture Fund (ABVF) and by several existing private shareholders.
Zymeworks president and CEO said the investment will allow them to further advance Azymetric, AlbuCORE and EFECT platforms, to accelerate the development of their protein therapeutics pipeline, and to ultimately make a difference in the lives of patients across the globe.